Browsing ICR Divisions by author "De Bono, Johann"
Now showing items 41-60 of 229
-
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.
Armstrong, AJ; Al-Adhami, M; Lin, P; Parli, T; Sugg, J; et al. (AMER MEDICAL ASSOC, 2020-02-01)IMPORTANCE: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic ... -
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; et al. (CIG MEDIA GROUP, LP, 2018-12-01)BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ... -
Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.
Maxwell, PJ; McKechnie, M; Armstrong, CW; Manley, JM; Ong, CW; et al. (AMER ASSOC CANCER RESEARCH, 2022-06-03)UNLABELLED: Inhibiting androgen signaling using androgen signaling inhibitors (ASI) remains the primary treatment for castrate-resistant prostate cancer. Acquired resistance to androgen receptor (AR)-targeted therapy ... -
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit, R; Wülfing, C; Castellano, D; Kramer, G; Eymard, J-C; et al. (ELSEVIER, 2021-08-24)BACKGROUND: There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD ... -
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Carreira, S; Porta, N; Arce-Gallego, S; Seed, G; Llop-Guevara, A; et al. (AMER ASSOC CANCER RESEARCH, 2021-11-01)PARP inhibitors are approved for treating advanced prostate cancers (APC) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed ... -
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.
Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; et al. (CELL PRESS, 2018-01-16)BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ... -
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki, H; Castellano, D; de Bono, J; Sternberg, CN; Fizazi, K; et al. (OXFORD UNIV PRESS, 2021-08-01)BACKGROUND: In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with ... -
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit, R; de Bono, J; Sternberg, CN; Fizazi, K; Tombal, B; et al. (MASSACHUSETTS MEDICAL SOC, 2019-12-26)BACKGROUND: The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously ... -
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.
Lorente, D; Omlin, A; Zafeiriou, Z; Nava-Rodrigues, D; Pérez-López, R; et al. (CIG MEDIA GROUP, LP, 2016-12-01)BACKGROUND: The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that ... -
CD38 in Advanced Prostate Cancers.
Guo, C; Crespo, M; Gurel, B; Dolling, D; Rekowski, J; et al. (ELSEVIER, 2021-02-01)BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been ... -
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati, A; D'Ambrosio, M; Troiani, M; Mosole, S; Pellegrini, L; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2020-05-01)The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic ... -
Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.
Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; et al. (KARGER, 2016-01-01)OBJECTIVES: We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small ... -
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno, P; Gurel, B; Pereira, R; Crespo, M; Rekowski, J; et al. (AMER ASSOC CANCER RESEARCH, 2020-09-28)PURPOSE: Cyclin-dependent kinase 12 (CDK12) aberrations have been reported as a biomarker of response to immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Herein, we characterize CDK12-mutated ... -
Chemical or Surgical Castration--Is This Still an Important Question?
Kolinsky, M; Rescigno, P; de Bono, JS (2016-04) -
Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
Rescigno, P; Rodrigues, DN; de Bono, JS (WILEY-BLACKWELL, 2017-01-01) -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Circulating cell-free DNA: Translating prostate cancer genomics into clinical care.
Gasi Tandefelt, D; de Bono, J (ELSEVIER, 2020-04-01)Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges ... -
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
Nanou, A; Coumans, FAW; van Dalum, G; Zeune, LL; Dolling, D; et al. (Impact Journals, LLC, 2018-04-10)PURPOSE: The presence of Circulating Tumor Cells (CTCs) in Castration-Resistant Prostate Cancer (CRPC) patients is associated with poor prognosis. In this study, we evaluated the association of clinical outcome in 129 CRPC ... -
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; et al. (ELSEVIER, 2018-07-01)BACKGROUND: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ... -
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.
Sundar, R; Custodio, A; Petruckevich, A; Chénard-Poirier, M; Ameratunga, M; et al. (ELSEVIER SCIENCE LONDON, 2018-03-01)AIMS: Advanced biliary tract carcinomas (ABC) are malignancies with limited effective therapies for advanced disease. There is little published evidence of outcomes of ABC patients participating in phase I clinical trials. ...